The FDA's approval of Colcrys
came with exclusive marketing rights for gout for 3 years and for familial Mediterranean fever for 7 years.
is part of Takeda s gout treatment portfolio, and was launched commercially in the U.
Currently, acute gout can be treated using NSAIDs, corticosteroids and Colcrys
, while doctors can prescribe uricosurics sulphinpyrazone, benzbromarone or xanthine oxidase inhibitors to treat chronic gout.
As a result of this partnership, Colchicine Tablets, USP will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys
Tablets, indicated for the prophylaxis and treatment of acute gout flares in adults, and the treatment of familial Mediterranean fever (FMF) in adults and children age four or older.
market in favor of the branded version, Colcrys
, marketed by URL Pharma.
Pillinger disclosed ties with Savient and Takeda, which markets colchicine as Colcrys
com/research/cc5711/gout_therapeutics) has announced the addition of the "Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys
to Drive Market" report to their offering.
But in October 2009, the Food and Drug Administration awarded a patent to URL Pharma (now owned by drug giant Takeda) for a branded formulation of colchicine, Colcrys
, to treat gout on the basis of safety studies that URL funded.
In light of the FDA's removal of unapproved colchicine from the market, [these outlying companies] must follow the lead of other Part-D insurers around the country and reclassify COLCRYS
as a tier-1 or 2 drug to ensure seniors have access to their vital gout medications" Martin wrote to the CEOs of the companies.
is part of Takeda's gout treatment portfolio, and was launched commercially in the U.
Once the older products are off the market, the only oral colchicine product that will be available is Colcrys
, marketed by Mutual Pharmaceuticals/URL Pharma, which was approved in 2009, after the company met the current drug approval requirements.